Detalhe da pesquisa
1.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
N Engl J Med
; 388(10): 898-912, 2023 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36884323
2.
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution.
Oncologist
; 29(4): e544-e552, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38141181
3.
Regional hyperthermia for soft tissue sarcoma - a survey on current practice, controversies and consensus among 12 European centers.
Int J Hyperthermia
; 41(1): 2342348, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653548
4.
Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.).
Cancer
; 129(22): 3564-3573, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37530385
5.
Evaluation of electronic patient-reported outcome assessment in inpatient cancer care: a feasibility study.
Support Care Cancer
; 31(10): 575, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37707633
6.
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
Int J Hyperthermia
; 40(1): 2236337, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37468132
7.
Fibrinogen-like protein 2 in gastrointestinal stromal tumour.
J Cell Mol Med
; 26(4): 1083-1094, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029030
8.
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
BMC Cancer
; 22(1): 511, 2022 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35524239
9.
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
BMC Cancer
; 22(1): 1302, 2022 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36514034
10.
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
Cancer
; 127(13): 2187-2195, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33974733
11.
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Oncologist
; 26(11): e2053-e2060, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34313371
12.
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
BMC Cancer
; 21(1): 89, 2021 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33482769
13.
Uncertainties that threaten the benefit/risk balance in early treatment lines for advanced or metastatic soft tissue sarcoma.
Future Oncol
; 17(21s): 7-10, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107768
14.
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa).
Eur J Cancer Care (Engl)
; 30(6): e13484, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34342924
15.
[Diagnosis and therapy of tumors with NTRK gene fusion]. / Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen.
Pathologe
; 42(1): 103-115, 2021 Feb.
Artigo
em Alemão
| MEDLINE | ID: mdl-33258061
16.
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(7): 923-934, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511981
17.
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 20(12): 1719-1729, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31704134
18.
TCR signalling network organization at the immunological synapses of murine regulatory T cells.
Eur J Immunol
; 47(12): 2043-2058, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28833060
19.
Guanine nucleotide-binding proteins of the G12 family shape immune functions by controlling CD4+ T cell adhesiveness and motility.
Immunity
; 30(5): 708-20, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19409815
20.
Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
Gynecol Oncol
; 150(1): 173-179, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29627080